396 Hits in 2.3 sec

Profile of Brian K. Kobilka and Robert J. Lefkowitz, 2012 Nobel Laureates in Chemistry

R. B. Clark
2013 Proceedings of the National Academy of Sciences of the United States of America  
Those of us that had been hammering away in the field for 40 years or more cannot deny the excitement in learning that Brian Kobilka, a former postdoctoral fellow of Robert Lefkowitz, in collaboration  ...  Brian Kobilka, after leaving his postdoctoral fellowship with Lefkowitz, quickly established his own reputation in the field by achieving the first animal knockouts of the β2AR and other adrenergic receptors  ... 
doi:10.1073/pnas.1221820110 pmid:23412332 pmcid:PMC3619354 fatcat:y2sprpli5bf6nb4e5pfmuzrrwe

Structure of the δ-opioid receptor bound to naltrindole

Sébastien Granier, Aashish Manglik, Andrew C. Kruse, Tong Sun Kobilka, Foon Sun Thian, William I. Weis, Brian K. Kobilka
2012 Nature  
The sequence identity within the transmembrane domains (TMs) between the m-OR and d-OR, the m-OR and k-OR, and the d-OR and k-OR is 76%, 73% and 74%, respectively 7 .  ...  The other interface, which is also observed in the k-OR, involves TM1, TM2 and helix 8.  ...  The sequence identity within the transmembrane domains (TMs) between the m-OR and d-OR, the m-OR and k-OR, and the d-OR and k-OR is 76%, 73% and 74%, respectively 7 .  ... 
doi:10.1038/nature11111 pmid:22596164 pmcid:PMC3523198 fatcat:iqus7o66k5fgniuspqwf4w6woa

Structure-based drug screening for G-protein-coupled receptors

Brian K. Shoichet, Brian K. Kobilka
2012 TIPS - Trends in Pharmacological Sciences  
Top row: four relatively potent ligands that resemble known chemotypes, with K i values from 9 nM to 2 uM. Bottom row: two novel chemotypes, with K i values of 1.1 and 3.3 uM.  ... 
doi:10.1016/ pmid:22503476 pmcid:PMC3523194 fatcat:uehc45h43netjioxuods5357ka

Crystal structure of the µ-opioid receptor bound to a morphinan antagonist

Aashish Manglik, Andrew C. Kruse, Tong Sun Kobilka, Foon Sun Thian, Jesper M. Mathiesen, Roger K. Sunahara, Leonardo Pardo, William I. Weis, Brian K. Kobilka, Sébastien Granier
2012 Nature  
The m-OR belongs to the c subfamily of class A G-protein-coupled receptors (GPCRs) with two closely related family members known as the dand k-opioid receptors 3 .  ...  This may explain why extremely potent opioids such as buprenorphine, with an inhibition constant (K i ) of 740 pM, diprenorphine (K i 72 pM), alvimopan (K i 350 pM) and etorphine (K i 230 pM) present rapid  ...  Nine of these have more direct interactions with the ligand (Fig. 3a-c) , and are conserved in the k-OR and d-OR.  ... 
doi:10.1038/nature10954 pmid:22437502 pmcid:PMC3523197 fatcat:cwnar4aptvg3bdoiktcwor3ikm

G Protein-coupled Receptors

Ulrik Gether, Brian K. Kobilka
1998 Journal of Biological Chemistry  
Sansan Lin for critical reading of the manuscript, and Jason Kobilka for preparation of the figures.  ...  .: 650-723-7069; Fax: 650-498-5092; E-mail: kobilka@ 1 The abbreviations used are: GPCR, G protein-coupled receptor; TM, transmembrane; NBD, N,NЈ-dimethyl-N-(iodoacetyl)-NЈ-(7-nitrobenz  ... 
doi:10.1074/jbc.273.29.17979 pmid:9660746 fatcat:s3lgmj3cxvetvatiqfwauotbke

A monoclonal antibody for G protein–coupled receptor crystallography

Peter W Day, Søren G F Rasmussen, Charles Parnot, Juan José Fung, Asna Masood, Tong Sun Kobilka, Xiao-Jie Yao, Hee-Jung Choi, William I Weis, Daniel K Rohrer, Brian K Kobilka
2007 Nature Methods  
Supplementary [ 3 H]dihydroalprenolol Isoproterenol K d ± S.E. K i [S.E. interval] (nM) (nM) !2AR 1.02 ± 0.09 290 [269-311] !2AR-Fab5 1.08 ± 0.05 329 [310-348]  ...  The IC 50 values used for calculations of K i values were obtained from means of pIC 50 values determined by nonlinear regression analysis and the S.E. interval from pIC 50 ± S.E.  ... 
doi:10.1038/nmeth1112 pmid:17952087 fatcat:dteziczhlzdghfvajugrxrkiri

Structure of a nanobody-stabilized active state of the β2 adrenoceptor

Søren G. F. Rasmussen, Hee-Jung Choi, Juan Jose Fung, Els Pardon, Paola Casarosa, Pil Seok Chae, Brian T. DeVree, Daniel M. Rosenbaum, Foon Sun Thian, Tong Sun Kobilka, Andreas Schnapp, Ingo Konetzki (+6 others)
2011 Nature  
BI-167107 is a full agonist that binds to the β 2 AR with a dissociation constant K d of 84 pM (Supplementary Figure 2A Crystallization of β 2 AR-T4L-Nb80 complex The β 2 AR was originally crystallized  ... 
doi:10.1038/nature09648 pmid:21228869 pmcid:PMC3058308 fatcat:ugn6vnqnlffhnlcuymtblfyuvq

G protein coupled receptor structure and activation

Brian K. Kobilka
2007 Biochimica et Biophysica Acta - Biomembranes  
G protein coupled receptors (GPCRs) are remarkably versatile signaling molecules. The members of this large family of membrane proteins are activated by a spectrum of structurally diverse ligands, and have been shown to modulate the activity of different signaling pathways in a ligand specific manner. In this manuscript I will review what is known about the structure and mechanism of activation of GPCRs focusing primarily on two model systems, rhodopsin and the β 2 adrenoceptor. Abbreviations:
more » ... 2 AR, beta 2 adrenoceptor; GPCR, G protein coupled receptor; TM, transmembrane ☆ Amino acid numbering: The position of β 2 AR residues are followed by the Ballesteros general number [1] in superscript, in the form X.YY, where X refers to the TM segment and YY to the position relative to the most highly conserved amino acid in the TM segment, which is assigned an arbitrary position of 50.
doi:10.1016/j.bbamem.2006.10.021 pmid:17188232 pmcid:PMC1876727 fatcat:karz2gdcjbdalkkfwizovsy3cq

Structural Insights into the Dynamic Process of β 2 -Adrenergic Receptor Signaling

Aashish Manglik, Tae Hun Kim, Matthieu Masureel, Christian Altenbach, Zhongyu Yang, Daniel Hilger, Michael T. Lerch, Tong Sun Kobilka, Foon Sun Thian, Wayne L. Hubbell, R. Scott Prosser, Brian K. Kobilka
2015 Cell  
doi:10.1016/j.cell.2015.04.043 pmid:25981665 pmcid:PMC4441853 fatcat:27h5fs6myjej3lkoc6undjmudy

Crystal structure of the β2 adrenergic receptor–Gs protein complex

Søren G. F. Rasmussen, Brian T. DeVree, Yaozhong Zou, Andrew C. Kruse, Ka Young Chung, Tong Sun Kobilka, Foon Sun Thian, Pil Seok Chae, Els Pardon, Diane Calinski, Jesper M. Mathiesen, Syed T. A. Shah (+8 others)
2011 Nature  
Kobilka, however, says that his functional assays show that the engineered proteins behave like the natural proteins.  ...  "But now that we know it happens, it's something we can study, " says Kobilka. The discovery could provide unexpected clues to the molecular mechanism of the cholera toxin.  ... 
doi:10.1038/nature10361 pmid:21772288 pmcid:PMC3184188 fatcat:xcw5tm22izg2xde7qcixbvhebu

Conformational complexity of G-protein-coupled receptors

Brian K. Kobilka, Xavier Deupi
2007 TIPS - Trends in Pharmacological Sciences  
G-protein-coupled receptors (GPCRs) are remarkably versatile signaling molecules. Members of this large family of membrane proteins respond to structurally diverse ligands and mediate most transmembrane signal transduction in response to hormones and neurotransmitters, and in response to the senses of sight, smell and taste. Individual GPCRs can signal through several Gprotein subtypes and through G-protein-independent pathways, often in a ligand-specific manner. This functional plasticity can
more » ... e attributed to structural flexibility of GPCRs and the ability of ligands to induce or to stabilize ligand-specific conformations. Here, we review what has been learned about the dynamic nature of the structure and mechanism of GPCR activation, primarily focusing on spectroscopic studies of purified human b 2 adrenergic receptor. Receptor conformations Proteins are often thought of as rigid structures, as in the lock-and-key model of receptor activation where the agonist
doi:10.1016/ pmid:17629961 fatcat:hu3x4njrofdmlgc3bitdwddpsq

Two functionally distinct α2-adrenergic receptors regulate sympathetic neurotransmission

Lutz Hein, John D. Altman, Brian K. Kobilka
1999 Nature  
for noradrenaline may re¯ect the difference in af®nity for noradrenaline between the a 2 -receptor subtypes: noradrenaline has a higher af®nity for the a 2C -subtype than for the a 2A -receptor 19 (K  ... 
doi:10.1038/46040 pmid:10647009 fatcat:6ysbuk2kcjh5vgj4asqp5thqte

Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein

Yan Zhang, Bingfa Sun, Dan Feng, Hongli Hu, Matthew Chu, Qianhui Qu, Jeffrey T. Tarrasch, Shane Li, Tong Sun Kobilka, Brian K. Kobilka, Georgios Skiniotis
2017 Nature  
This network facilitates the stabilization of the TM core and is positioned to detect peptide binding through potential interactions of R 2.60b (K 2.60b in GCGR) with residue E9 at the peptide N-terminus  ... 
doi:10.1038/nature22394 pmid:28538729 pmcid:PMC5587415 fatcat:cyx2nqh5o5gbfnfev5lnnx3dsu

G Protein-Coupled Receptors: Functional and Mechanistic Insights Through Altered Gene Expression

1998 Physiological Reviews  
Rohrer, Daniel K., and Brian K. Kobilka. G-Protein Coupled Receptors: Functional and Mechanistic Insights Through Altered Gene Expression. Physiol. Rev. 78: I. Introduction 35 II.  ...  K. DERIEL, M. W. ADLER, AND C. L.  ... 
doi:10.1152/physrev.1998.78.1.35 pmid:9457168 fatcat:7lvwajjtbncbhccfvabgyeiyiu

Structural insights into adrenergic receptor function and pharmacology

Brian K. Kobilka
2011 TIPS - Trends in Pharmacological Sciences  
It has been over 50 years since Sir James Black developed the first beta adrenergic receptor (βAR) blocker to treat heart disease. At that time, the concept of cell-surface receptors was relatively new and not widely accepted, and most of the tools now used to characterize plasma membrane receptors had not been developed. There has been remarkable progress in receptor biology since then, including the development of radioligand binding assays, the biochemical characterization of receptors as
more » ... crete membrane proteins, and the cloning of the first G protein-coupled receptors (GPCRs), which led to the identification of other members of the large family of GPCRs. More recently, progress in GPCR structural biology has led to insights into the three-dimensional structures of βARs receptors in both active and inactive states. Despite all of this progress, the process of developing a drug for a particular GPCR target has become more complex, timeconsuming, and expensive.
doi:10.1016/ pmid:21414670 pmcid:PMC3090711 fatcat:uon2nl2kmnbzncqklhyxl2qrum
« Previous Showing results 1 — 15 out of 396 results